MARK LENKER

FY27 Appropriations and policy for BARDA, IBMSC, SNS, SRF/Project BioShield; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; MCM Priority Review Voucher

Women's health and OTC product development

Federal funding for medical device to reduce and prevent respiratory infections.

Rare Disease Policy and FDA Policy.

FY27 Defense Appropriations and FY27 NDAA for warfighter brain health, including CTE, mTBI, TBI, and warfighter cognitive optimization for preparedness and battlefield operations.

FY27 Appropriations and policy for BARDA, IBMSC, SNS, SRF/Project BioShield; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; MCM Priority Review Voucher

Federal funding for medical device to reduce and prevent respiratory infections.

FY27 Appropriations and policy for BARDA, IBMSC, SNS, SRF/Project BioShield; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; Rare Pediatric Disease Priority Review Voucher; MCM Priority Review Voucher

Rare Disease Policy and FDA Policy.

FY26 and FY27 Defense Appropriations and FY27 NDAA for warfighter brain health for CTE, TBI, and related.

Clinical trial guidance for ultra-rare and rare diseases.

Federal funding for medical device to reduce respiratory infections.

FY26 Defense Appropriations and FY26 NDAA for warfighter brain health for CTE, TBI, and related.

Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 26 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher; MFN drug pricing; tariffs

Rare disease issues; FDA policies

Federal funding for medical device to reduce respiratory infections.

FY26 Defense Appropriations and FY26 NDAA for warfighter brain health for CTE, TBI, and related.

Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 26 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher

Federal funding for medical device to reduce respiratory infections.

FY26 Defense Appropriations and FY26 NDAA for warfighter brain health for CTE, TBI, and related.

Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 26 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher

Federal funding for medical device to reduce respiratory infections.

FY26 Defense Appropriations and FY26 NDAA for warfighter brain health for CTE, TBI, and related.

Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 26 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher

Funding for Prosthetic Research for Infection Treatment and Prevention.

Funding for Prosthetic Research for Infection Treatment and Prevention.

Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 25 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher

Funding for Prosthetic Research for Infection Treatment and Prevention.

Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 25 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher

Funding for Prosthetic Research for Infection Treatment and Prevention.

Funding for genetic testing and carrier screening, women's health, diagnostic equity.

Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 25 LHHS appropriations; MCM PRV; SUPER BUGS Act

Funding for Prosthetic Research for Infection Treatment and Prevention.

Funding for genetic testing and carrier screening, women's health, diagnostic equity, FY 24 appropriations, FY 25 appropriations, FY 25 NDAA

Funding for genetic testing and carrier screening, women's health, diagnostic equity, FY 24 appropriations, FY 25 appropriations, FY 25 NDAA

Funding for medical devices for hemorrhages; provisions in FY24 NDAA and FY24 Defense Appropriations

Oversight of the Strategic National Stockpile to promote safer and more effective treatments in the stockpile; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; FY 24 LHHS appropriations; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; increasing domestic manufacturing and onshoring of treatments and their components; BARDA funding and oversight; IBMSC funding and oversight; FY 25 LHHS appropriations; MCM PRV

Funding for medical devices for hemorrhages; provisions in FY24 NDAA and FY24 Defense Appropriations

Oversight of the Strategic National Stockpile to promote safer and more effective treatments in the stockpile; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; FY 24 LHHS appropriations; funding and incentives for MCM development; AMR issues

Funding for medical devices for hemorrhages; provisions in FY24 NDAA and FY24 Defense Appropriations

Oversight of the Strategic National Stockpile to promote safer and more effective treatments in the stockpile; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; FY 24 LHHS appropriations; funding and incentives for MCM development; AMR issues

Funding for medical devices for hemorrhages; provisions in FY24 NDAA and FY24 Defense Appropriations

Oversight of the Strategic National Stockpile to promote safer and more effective treatments in the stockpile; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; FY 24 LHHS appropriations; funding and incentives for MCM development; AMR issues

Funding for medical devices for hemorrhages; provisions in FY24 NDAA and FY24 Defense Appropriations

Funding for medical devices for hemorrhages; provisions in FY24 NDAA and FY24 Defense Appropriations

Funding for medical devices for hemorrhages; provisions in FY24 NDAA and FY24 Defense Appropriations

Oversight of the Strategic National Stockpile to promote safer and more effective treatments in the stockpile; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; FY 24 LHHS appropriations; funding and incentives for MCM development; AMR issues

Oversight of the Strategic National Stockpile to promote safer and more effective treatments in the stockpile; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; FY 24 LHHS appropriations; funding and incentives for MCM development; AMR issues